Watch here

Neuren Pharmaceuticals (ASX: NEU) was pleased to participate in the 43rd Annual J.P. Morgan Healthcare Conference, held from 13 to 16 January 2025, in San Francisco.

Neuren delivered a presentation at the Conference and engaged in one-on-one meetings with investors and industry peers, showcasing its development pipeline for NNZ-2591 and robust financial growth profile from DAYBUE (trofinetide).